GlioCART is a University of Basel spin-off focused on translating a dual-action CAR-T therapy for glioblastoma into clinical application by combining tumor targeting with immune microenvironment reprogramming.
Our mission is to achieve durable clinical benefit for patients with glioblastoma.
Employees
1-10Org chart
Collapse
No reports!
Teams
This company has no teams yet
Offices
This company has no offices yet
